A new study published in The Lancet reported that Boehringer Ingelheim’s BI 695501 (biosimilar adalimumab) has similar safety and efficacy to reference adalimumab in patients with Crohn’s disease.
A Matter of Taste: IPONZ Decision Serves Up Important Reminders on Patent Practice
Suntory Holdings Limited [2024] NZIPOPAT 11 Date of decision: 8 October 2024 Body: Intellectual Property Office of New Zealand Adjudicator:...